RHHBY
ROCHE HLDG LTD SPONS ADR
$51.65
+0.58%
No data for this timeframe.
Vol
Inst. Holders3 funds
Inst. Value$108.2M
Inst. Activity0 buys / 1 sells
Prev Close $51.35
Recent Activity
Inst.
Pacer Advisors, Inc. — EXIT
0 shares ($0.00)
Inst.
MAI Capital Management — TRIM
27,682 shares ($1.1M)
Jun 7, 2026
clinical_trial_readout
Results Pending: Polatuzumab Vedotin (Phase 3) — Completed 38d ago
Trial: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophospham
Jun 3, 2026
Event
Columvi
WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), including serious or fatal react
Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$56.66
Current $51.65
Low $46.00
Median $59.00
High $67.00
7 analysts
$46.00
$67.00
Analyst Ratings
5Strong Buy
9Buy
10Hold
2Sell
1Strong Sell
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $2.95 | $2.40 — $3.27 | -6% YoY | 3 |
| Next FY | $3.23 | $2.55 — $3.60 | 9% YoY | 4 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Aristotle Capital Management, LLC | $102.1M | — |
| RHUMBLINE ADVISERS | $4.9M | — |
| PNC FINANCIAL SERVICES GROUP, | $1.2M | — |
3 institutional holders with $108.2M total value (2,186,285 shares) as of 2026-Q1. Top holders: Aristotle, RHUMBLINE, PNC.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Aristotle Capital Management, LLC | 2,063,885 | $102.1M | 94.4% | — |
| 2 | RHUMBLINE ADVISERS | 98,944 | $4.9M | 4.5% | — |
| 3 | PNC FINANCIAL SERVICES GROUP, INC. | 23,456 | $1.2M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Pacer Advisors, Inc. | EXIT | 1,178,534 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MAI Capital Management | TRIM | 61,193 | 27,682 | -54.8% | $1.1M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 52% buy across 27 analysts — 5 strong buy, 9 buy, 10 hold, 2 sell, 1 strong sell. No current recommendation available.
Analyst Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$56.66 mean target
$46.00 Low
$67.00 High
| Metric | Value |
|---|---|
| Current Price | $51.65 |
| Target Low | $46.00 |
| Target Mean | $56.66 |
| Target Median | $59.00 |
| Target High | $67.00 |
| # Analysts | 7 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $15.6B | 0.6% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $15.5B | 4.0% | — |
| Current FY 2026-12-31 |
$2.95 | $2.40 | $3.27 | -6.4% | -0.1% | 2↑ 0↓ | $62.6B | 1.7% | 3 |
| Next FY 2027-12-31 |
$3.23 | $2.55 | $3.60 | 9.2% | +0.0% | 2↑ 0↓ | $65.1B | 4.1% | 4 |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 10 | 2 | 1 | 52% | |
| May 1, 2026 | 5 | 9 | 10 | 2 | 1 | 52% | |
| Apr 1, 2026 | 5 | 9 | 9 | 3 | 1 | 52% | |
| Mar 1, 2026 | 6 | 9 | 9 | 4 | 1 | 52% | |
| Feb 1, 2026 | 7 | 9 | 8 | 4 | 1 | 55% | |
| Jan 1, 2026 | 6 | 9 | 8 | 3 | 1 | 56% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 13, 2026
Clinical Trial
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Phase Phase 3 — COMPLETED
Jun 13, 2026
Clinical Trial
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Phase Phase 2 — COMPLETED
Jun 12, 2026
Clinical Trial
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Phase Phase 2 — TERMINATED
Jun 12, 2026
Clinical Trial
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Phase Phase 3 — COMPLETED
Jun 11, 2026
Clinical Trial
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Phase Phase 3 — TERMINATED
Jun 7, 2026
clinical_trial_readout
Results Pending: Polatuzumab Vedotin (Phase 3) — Completed 38d ago
Trial: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Ri
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Ranibizumab (Phase 3)
Trial: A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Sponsor: EyeBiotec
Jun 3, 2026
FDA
Columvi
WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Pre
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: Giredestrant (Phase 2)
Trial: A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Sponsor: Hoffmann-La Roche
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITI
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: Alectinib (Phase 2)
Trial: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Ho
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: Satralizumab (Phase 2)
Trial: A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
Sponsor: Hoffmann-La Roche
Phase: Phase 2 | Stat
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: RO7204239 (Phase 2)
Trial: A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide
May 30, 2026
clinical_trial_readout
T-90d Trial Readout: Giredestrant (Phase 2)
Trial: A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Sponsor: Hoffmann-La Roche
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITI
May 30, 2026
clinical_trial_readout
T-90d Trial Readout: Alectinib (Phase 2)
Trial: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Ho
May 29, 2026
FDA
Herceptin
WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL T
May 29, 2026
FDA
Herceptin Hylecta
WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full
May 28, 2026
clinical_trial_readout
T-90d Trial Readout: Satralizumab (Phase 2)
Trial: A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
Sponsor: Hoffmann-La Roche
Phase: Phase 2 | Stat
May 26, 2026
clinical_trial_readout
T-90d Trial Readout: RO7204239 (Phase 2)
Trial: A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide
May 22, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Status: Opinion
May 18, 2026
FDA
HERCEPTIN HYLECTA
Supplemental Approval — Labeling — TRASTUZUMAB AND HYALURONIDASE-OYSK — INJECTABLE — SUBCUTANEOUS
May 12, 2026
clinical_trial_readout
T-90d Trial Readout: Zifibancimig (Phase 2)
Trial: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
Sponsor: Hoffmann-La Roche
Phase: Phase 2 | Status: ACT
May 12, 2026
short_interest
FTD: RHHBY — 19,627 shares ($1.0M) failed to deliver
Settlement: 20260512, Price: $51.41, FTD Value: $1,009,024.07, ROCHE HLDG LTD SPONS ADR
May 8, 2026
clinical_trial_readout
Results Pending: Polatuzumab Vedotin (Phase 3) — Completed 8d ago
Trial: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Ri
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Zifibancimig (Phase 2)
Trial: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
Sponsor: Hoffmann-La Roche
Phase: Phase 2 | Status: ACT
Apr 30, 2026
FDA
PERJETA
WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY Left Ventricular Dysfunction: PERJETA can cause subclinical and clinical cardiac failu